Results 131 to 140 of about 17,579 (227)

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?

Hepatic Medicine: Evidence and Research, 2015
Sujit V Janardhan, Nancy S Reau Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA Abstract: Chronic hepatitis C virus (HCV) infection represents a global ...
Janardhan SV, Reau NS
doaj  

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis [PDF]

, 2020
Barclay, Stephen T., Boyle, Alison, Datta, Shouren, Heydtmann, Mathis, Marra, Fiona, Peters, Erica, Priest, Matthew, Ritchie, Trina   +7 more
core   +3 more sources

Hepatitis C virus NS5A and core protein induce fibrosis-related genes regulation on Huh7 cells through activation of LX2 cells

Annals of Hepatology
Introduction and Objectives: Liver fibrosis remains a complication derived from a chronic Hepatitis C Virus (HCV) infection even when it is resolved, and no liver antifibrotic drug has been approved.
Tania G. Heredia-Torres, Veronica Alvarado-Martínez, Ana R. Rincón-Sánchez, Sonia A. Lozano-Sepúlveda, Kame A. Galán-Huerta, Daniel Arellanos-Soto, Ana M. Rivas-Estilla   +6 more
doaj   +1 more source

Expression and function of osteopontin variants in HCV-related liver disease and hepatocellular carcinoma. [PDF]

, 2010
Osteopontin (OPN) is a highly secreted multi-functional sialoprotein that is widely expressed in tissues, blood and urine. It is involved in a number of normal physiological functions, but is also significantly elevated in a number of cancers.
Phillips, Renee Jade
core   +1 more source

Phospholipid-driven conformational switching of HCV NS5A links protein folding to replication membrane remodeling. [PDF]

Sci Adv
Bulankina AV, Richter RM, Nettles JH, Yamane D, Grimm C, Karami Y, Stanton RA, Introini B, Hermann J, Charif H, König MS, Stroß C, Ortiz C, Kraus N, Wood D, Galceran F, Abele R, Maigret B, Schinazi RF, Zeuzem S, Biondi RM, Yi M, Tampé R, Kudryashev M, Welsch C.   +24 more
europepmc   +1 more source

Linezolid for multidrug-resistant tuberculosis. [PDF]

, 2013
Cox, H, Ford, N, Goemaere, E, Hughes, J
core   +2 more sources

Generation of a HiBiT-expressing recombinant rat hepacivirus supporting both in vivo and in vitro infection. [PDF]

PLoS Pathog
Akaike Y, Tanaka T, Kasai H, Yamashita A, Matsuura Y, Moriishi K.   +5 more
europepmc   +1 more source

Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies. [PDF]

J Virol
Kennedy MJ, Wolfisberg R, Lundsgaard EA, Thorselius CE, Collignon L, Nielsen L, Holmbeck K, Bukh J, Scheel TKH.   +8 more
europepmc   +1 more source

Molecular Maneuvers and Host Sabotage: A Comprehensive Review of CSFV's Multifaceted Strategies to Subvert Immune Defenses and Cellular Metabolism. [PDF]

Viruses
Sun W, Xu L, Li J.
europepmc   +1 more source

Screening and Characterization of TAT-Fused Nanobodies Targeting Bovine Viral Diarrhea Virus NS3/NS5A for Antiviral Application. [PDF]

Biomolecules
Dong Q, Xiao Y, Liu Z, Zhang W, Wu A, Zhang H, Sheng J.   +6 more
europepmc   +1 more source